Seres Therapeutics (NASDAQ:MCRB) Stock Price Crosses Below 200 Day Moving Average – Here’s What Happened

Seres Therapeutics, Inc. (NASDAQ:MCRB)’s share price crossed below its two hundred day moving average during trading on Friday . The stock has a two hundred day moving average of $14.41 and traded as low as $7.14. Seres Therapeutics shares last traded at $7.46, with a volume of 76,902 shares.

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on the company. Chardan Capital reiterated a “neutral” rating and issued a $6.00 price objective (up from $1.25) on shares of Seres Therapeutics in a report on Thursday, May 8th. The Goldman Sachs Group dropped their target price on Seres Therapeutics from $20.00 to $15.00 and set a “sell” rating for the company in a report on Friday, March 14th. Finally, StockNews.com upgraded Seres Therapeutics from a “sell” rating to a “hold” rating in a report on Friday, May 9th. Two investment analysts have rated the stock with a sell rating, three have given a hold rating and one has assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and an average target price of $73.67.

Seres Therapeutics Stock Performance

The stock has a market cap of $65.14 million, a P/E ratio of -32.43 and a beta of 2.89. The firm has a 50-day moving average price of $10.93 and a 200-day moving average price of $14.40.

Seres Therapeutics (NASDAQ:MCRB) last issued its earnings results on Wednesday, May 7th. The biotechnology company reported ($2.24) EPS for the quarter, missing the consensus estimate of ($0.67) by ($1.57). On average, research analysts predict that Seres Therapeutics, Inc. will post -0.38 earnings per share for the current year.

Hedge Funds Weigh In On Seres Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of MCRB. Millennium Management LLC lifted its position in Seres Therapeutics by 77.2% during the fourth quarter. Millennium Management LLC now owns 1,810,719 shares of the biotechnology company’s stock valued at $1,505,000 after purchasing an additional 788,762 shares in the last quarter. Vontobel Holding Ltd. lifted its position in Seres Therapeutics by 137.6% during the fourth quarter. Vontobel Holding Ltd. now owns 938,295 shares of the biotechnology company’s stock valued at $780,000 after purchasing an additional 543,469 shares in the last quarter. Geode Capital Management LLC lifted its position in Seres Therapeutics by 8.8% during the fourth quarter. Geode Capital Management LLC now owns 1,510,432 shares of the biotechnology company’s stock valued at $1,256,000 after purchasing an additional 121,793 shares in the last quarter. Charles Schwab Investment Management Inc. lifted its position in Seres Therapeutics by 15.6% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 865,825 shares of the biotechnology company’s stock valued at $720,000 after purchasing an additional 117,107 shares in the last quarter. Finally, Invesco Ltd. lifted its position in Seres Therapeutics by 193.2% during the first quarter. Invesco Ltd. now owns 136,572 shares of the biotechnology company’s stock valued at $96,000 after purchasing an additional 89,995 shares in the last quarter. 59.34% of the stock is currently owned by hedge funds and other institutional investors.

Seres Therapeutics Company Profile

Seres Therapeutics, Inc, a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state.